Research from Hebei Medical University, Department of Immunology yields new data on respiratory syncytial virus vaccines
2007 NOV 20 -- Current study results from the report, 'Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2,' have been published. According to recent research published in the journal Vaccine, "Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract illness in young children. We have engineered a recombinant candidate vaccine G1F/M2, consisting of a cytotoxic T lymphocyte (CTL) epitope of RSV-M2 protein and a domain of RSV-G protein." "In this study, the long-term immunogenicity and protective effect were evaluated. In G1F/M2-immunized mice, special antibodies lasted for more than 19 weeks, and the IgG1/IgG2a ratio remained a balanced level till the end of the study, suggesting mixed Th1/Th2 type of responses. Concomitantly, G1F/M2 elicited long-lived RSV-specific CTL activity that was detectable at 12 weeks after the final immunization. Stronger CTL responses were induced with immunization once more at 13 weeks after the last immunization in G1F/M2-primed mice than those in F/M2-primed mice. These results suggest that G1F/M2-induced long-lasting balanced humoral and cellular immunity responses, and immunological memory in mice. Furthermore, following RSV challenge, long-term protective efficacy was observed. RSV replication in lungs of G1F/M2-primed mice elicited also mixed Th1/Th2 responses, a property that is considered advantageous for the safety of an RSV vaccine," wrote R. Zeng and colleagues, Hebei Medical University, Department of Immunology. The researchers concluded: "Therefore, G1F/M2 is a promising RSV subunit vaccine." Zeng and colleagues published their study in Vaccine (Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine, 2007;25(42):7422-8). For additional information, contact R. Zeng, Hebei Medical University, Dept. of Immunology, Shijiazhuang 050017, China. The publisher's contact information for the journal Vaccine is: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: People's Republic of China, Shijiazhuang, Respiratory Syncytial Virus Vaccines, Biotechnology, Immunology, Infectious Disease, Proteomics, Pulmonology, Respiratory Syncytial Virus, Vaccines. This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2007, Life Science Weekly via NewsRx.com.
|
